|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17).
|
7682097 |
1993 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In an attempt to get new insights into the function of the wild-type PML protein and to investigate whether it displays an altered expression pattern in neoplasms other than acute promyelocytic leukemia, we stained a large number of normal and neoplastic human tissues with a new murine monoclonal antibody (PG-M3) directed against the amino-terminal region of PML.
|
8952536 |
1996 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The resulting fusion genes encode the two structurally unique PML/RARalpha and RARalpha/PML fusion proteins as well as aberrant PML gene products, the respective pathogenetic roles of which have not been elucidated.
|
9144232 |
1997 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The architecture of PML nuclear bodies appears to be disrupted in APL cells that bear the t(15; 17), thus resulting in a change of the nuclear staining pattern from speckled (wild-type PML protein) to microgranular (PML-RARalpha fusion protein).
|
9354674 |
1997 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our studies demonstrated IR at 20Gy, and cisplatin at 6 micrograms/ml caused more than 5-10 fold increases in PML protein expression in the PML Oncogenic Domain (POD) by immunofluorescent staining.
|
9398618 |
1997 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nevertheless, staining for promyelocytic leukemia (PML) protein will detect acute PML with t(15;17) because the microspeckled nuclear labeling pattern for PML-RARalpha is highly distinctive.
|
11781220 |
2002 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The occurrence of HIPK domains in PML-/- fibroblasts reveals their independence from the PML protein.
|
12907596 |
2003 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
An immunohistochemical study of PML protein in these tumors revealed a disrupted pattern of PML bodies in a nuclear diffuse form, as observed in APL cells.
|
15104675 |
2004 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
PML protein is typically localized within discrete speckled nuclear structures termed PML nuclear bodies (NBs).
|
15459016 |
2005 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fluorescence in situ hybridization with a PML/RARA dual-color DNA probe showed the fusion signals on der(15) and the residual PML signals on der(22).
|
16737919 |
2006 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promyelocytic leukemia (PML) has been implicated in a variety of functions, including control of TP53 function and modulation of cellular senescence.
|
16778193 |
2006 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
In human cytomegalovirus (HCMV) infection, the IE1 (for "immediate-early 1") protein has a marked effect on PML bodies via de-SUMOylation of PML protein.
|
16870775 |
2006 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that the increased expression of SUMO-1 in rheumatoid arthritis (RA) synovial fibroblasts (SFs) contributes to the resistance of these cells against Fas-induced apoptosis through increased SUMOylation of nuclear PML protein and increased recruitment of the transcriptional repressor DAXX to PML NBs.
|
17360386 |
2007 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, methyl 2,5-dihydromethylcinnimate (2,5-MeC), a tyrosine kinase inhibitor, enhanced expression and/or stability of PML proteins and induced PML-NB formation in p53 null H1299 cells established from non-small cell lung cancer (NSCLC) and wild-type p53-expressing U2OS cells derived from osteosarcoma.
|
17585903 |
2007 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the expression of proto-oncogene PML and HLA class I molecules were concordantly upregulated and the expression of PML gene might be one of the mechanisms that leads to the increased expression of class I antigen in HCC.
|
17767548 |
2007 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The promyelocytic leukemia (PML) tumour suppressor is the organiser of PML nuclear bodies, which are domains the precise functions of which are still disputed.
|
17878236 |
2007 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using two different human neuroblastoma cell lines, SH-SY5Y and LA-N-5, we show here that PML protein leads to the formation of nuclear bodies (PML-NB) after only 1 h of retinoic acid treatment and that this formation is mediated by the extracellular signal-regulated kinase (ERK) pathway.
|
17986232 |
2008 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with acute promyelocytic leukemia (APL), the RARalpha gene is fused with the promyelocytic leukemia (PML) gene via the t(15;17) translocation, resulting in the expression of a PML/RARalpha fusion protein.
|
18212063 |
2008 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PML-regulated apoptotic mechanisms in GBM cells transfected with plasmids expressing the PML gene were examined.
|
18812519 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although it is well defined that PML NB is a site recruiting sumoylated proteins, the mechanism by which PML protein regulates the process remains unclear.
|
19150978 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies revealed that both SUMO modification sites and SUMO interaction motifs in the promyelocytic leukemia (PML) protein are required for PML body formation.
|
19793919 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of the promyelocytic leukemia (PML) protein and its associated PML nuclear body (PML-NB) by chemotherapy and irradiation-induced DNA repair signaling correlated with the upregulation of HBV pregenomic transcription, HBV-core expression, and HBV DNA replication.
|
19808906 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecularly, the disease is characterized by a fusion protein, promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha that results from a balanced reciprocal translocation between the PML gene on chromosome 15 and the RAR-alpha (RARA) gene on chromosome 17.
|
19840521 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the 398T allele degrades PML tumor suppressor protein more efficiently than the 398C allele and shows a relatively stronger binding to PML.
|
20625391 |
2010 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Promyelocytic leukemia protein (PML) tumor suppressor is upregulated in several forms of cellular senescence, however the mechanism of its induction is elusive.
|
20699642 |
2010 |